8-K: Sangamo Gets Nasdaq Extension to Avoid Delisting

Sangamo Therapeutics, Inc. received a 180-day extension from Nasdaq until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement.

Summary

• Sangamo Therapeutics, Inc. (SGMO) received an Extension Notice from The Nasdaq Stock Market LLC on October 29, 2025.
• The notice grants a 180-day extension, until April 27, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.
• The company was previously notified on April 30, 2025, that it was not in compliance with this requirement, with an initial deadline of October 27, 2025.
• To regain compliance, the common stock's bid price must close at $1.00 per share or more for a minimum of 10 consecutive trading days before April 27, 2026.
• The Extension Notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market.
• If compliance is not regained by April 27, 2026, Nasdaq is expected to issue a delisting notification, which the company may appeal to a hearings panel.

Sentiment

Score: 4

Explanation: While an extension was granted, the underlying issue of non-compliance with Nasdaq's minimum bid price requirement persists, indicating ongoing challenges for the company. The extension provides a temporary reprieve but does not resolve the fundamental problem, leading to continued uncertainty.

Positives

• The company has been granted a 180-day extension, avoiding immediate delisting from The Nasdaq Capital Market.
• The extension provides additional time, until April 27, 2026, to implement strategies to regain compliance with the minimum bid price requirement.

Negatives

• The company failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the initial deadline of October 27, 2025.
• There is no assurance that the company will regain compliance during the additional 180-day period or maintain compliance with other Nasdaq listing requirements.
• Failure to regain compliance could lead to delisting, which may negatively impact liquidity and investor confidence.

Risks

• Inability to regain compliance with Nasdaq's minimum bid price requirement by April 27, 2026.
• Potential delisting of the common stock from The Nasdaq Capital Market if compliance is not achieved.
• Uncertainty regarding the outcome of any appeal to a Nasdaq hearings panel if a delisting determination is made.
• Inability to maintain compliance with any other Nasdaq listing requirements.
• Factors outlined under 'Risk Factors' in the company's most recent Annual Report on Form 10-K and subsequent Form 10-Q filings.

Future Outlook

The company intends to cure the Minimum Bid Price Requirement by April 27, 2026. However, there is no assurance that compliance will be regained during this additional period or that the company will maintain compliance with any other Nasdaq listing requirements. If compliance is not regained, the company expects a delisting notification and may appeal the determination.

Management Comments

• The company intends to cure the Minimum Bid Price Requirement by April 27, 2026.

Industry Context

Maintaining listing standards, particularly minimum bid price requirements, is a common challenge for smaller biotechnology companies whose stock prices can be volatile due to clinical trial results, regulatory approvals, and funding rounds. Extensions are often granted, but the underlying issue reflects market perception and financial health, which can impact a company's ability to attract capital and maintain investor confidence compared to larger, more stable industry players.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's listing status and potential delisting, which could impact stock liquidity and value.
• The company's ability to attract new investors or raise capital may be affected by the ongoing compliance issues.

Next Steps

• Work to ensure the common stock's bid price closes at $1.00 or more for a minimum of 10 consecutive trading days by April 27, 2026.
• If delisted, potentially appeal the delisting determination to a Nasdaq hearings panel.

Key Dates

Recommendation

The extension provides a temporary reprieve from immediate delisting, but the underlying issue of failing to meet Nasdaq's minimum bid price requirement remains. While the company has a chance to regain compliance, the outcome is uncertain, warranting a cautious 'hold' position for investors. A 'buy' would be premature given the risk, and a 'sell' might be an overreaction given the granted extension.

Keywords

Sangamo Therapeutics, SGMO, Nasdaq, delisting, minimum bid price, compliance, stock market, biotechnology, SEC filing